Terms: = Colorectal cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
225 results:
1. DB-1310, an ADC comprised of a novel anti-her3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of her3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
2. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
[TBL] [Abstract] [Full Text] [Related]
3. Endorobotic submucosal dissection of rectal lesions using the single port robot DaVinci-SP: initial experience of the first 10 cases.
Ozgur I; Cheong JY; Liska D; Holubar S; Valante MA; Steele SR; Gorgun E
ANZ J Surg; 2024 Apr; 94(4):691-696. PubMed ID: 38012087
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
5. Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous colorectal Adenocarcinoma Cells.
Kuracha MR; Govindarajan V; Loggie BW; Tobi M; McVicker BL
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569713
[TBL] [Abstract] [Full Text] [Related]
6. AMT-562, a Novel her3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for her3-expressing Tumors.
Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
[TBL] [Abstract] [Full Text] [Related]
7. Disparities in geospatial patterns of cancer care within urban counties and structural inequities in access to oncology care.
McGee-Avila JK; Richmond J; Henry KA; Stroup AM; Tsui J
Health Serv Res; 2023 Aug; 58 Suppl 2(Suppl 2):152-164. PubMed ID: 37208901
[TBL] [Abstract] [Full Text] [Related]
8. her3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
Desai O; Wang R
Oncotarget; 2023 May; 14():439-443. PubMed ID: 37163206
[TBL] [Abstract] [Full Text] [Related]
9. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
[TBL] [Abstract] [Full Text] [Related]
10. MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the erbb3/AKT axis.
Candiello E; Reato G; Verginelli F; Gambardella G; D Ambrosio A; Calandra N; Orzan F; Iuliano A; Albano R; Sassi F; Luraghi P; Comoglio PM; Bertotti A; Trusolino L; Boccaccio C
Mol Oncol; 2023 Jul; 17(7):1280-1301. PubMed ID: 36862005
[TBL] [Abstract] [Full Text] [Related]
11. Dual-targeting therapy against her3/MET in human colorectal cancers.
Yamasaki A; Miyake R; Hara Y; Okuno H; Imaida T; Okita K; Okazaki S; Akiyama Y; Hirotani K; Endo Y; Masuko K; Masuko T; Tomioka Y
Cancer Med; 2023 Apr; 12(8):9684-9696. PubMed ID: 36751113
[TBL] [Abstract] [Full Text] [Related]
12. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
13. ErbB4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signaling.
Ghaemi Z; Soltani BM; Mowla SJ
Tumour Biol; 2022; 44(1):215-230. PubMed ID: 36442170
[TBL] [Abstract] [Full Text] [Related]
14. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and erbb3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Propper DJ; Gao F; Saunders MP; Sarker D; Hartley JA; Spanswick VJ; Lowe HL; Hackett LD; Ng TT; Barber PR; Weitsman GE; Pearce S; White L; Lopes A; Forsyth S; Hochhauser D
Br J Cancer; 2023 Jan; 128(2):245-254. PubMed ID: 36352028
[TBL] [Abstract] [Full Text] [Related]
15. Pertuzumab Plus Trastuzumab in Patients With colorectal cancer With
Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
[TBL] [Abstract] [Full Text] [Related]
16. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
[TBL] [Abstract] [Full Text] [Related]
17. EGFR, HER2, and her3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.
Ye P; Li F; Wei Y; Zhang Y; Cui J; Dai R; Chen H; Xie J; Cai P
Sci Rep; 2022 Jul; 12(1):12894. PubMed ID: 35902718
[TBL] [Abstract] [Full Text] [Related]
18. Negative Ultraselection of Patients With
Randon G; Maddalena G; Germani MM; Pircher CC; Manca P; Bergamo F; Giordano M; Sposetti C; Montagna A; Vetere G; Zambelli L; Rasola C; Boccaccino A; Pagani F; Ambrosini M; Massafra M; Fontanini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
JCO Precis Oncol; 2022 Apr; 6():e2200037. PubMed ID: 35544729
[TBL] [Abstract] [Full Text] [Related]
19. her3 overexpression and hypomethylation in colorectal adenocarcinoma.
Othman R; Mohtarrudin N; Ahmad Zubir NM; Seow HF; Ngan KW; Osman M
Malays J Pathol; 2022 Apr; 44(1):67-74. PubMed ID: 35484888
[TBL] [Abstract] [Full Text] [Related]
20. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
[Next]
